# Drug-drug Interaction Study of KL1333 in Healthy Subjects

> **NCT04643249** · PHASE1 · COMPLETED · sponsor: **Abliva AB** · enrollment: 14 (actual)

## Conditions studied

- Mitochondrial Disease

## Interventions

- **DRUG:** KL1333
- **DRUG:** Flurbiprofen
- **DRUG:** Dextromethorphan
- **DRUG:** Bupropion
- **DRUG:** Midazolam injection
- **DRUG:** Omeprazole
- **DRUG:** Caffeine
- **DRUG:** Repaglinide

## Key facts

- **NCT ID:** NCT04643249
- **Lead sponsor:** Abliva AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-10
- **Primary completion:** 2020-12-17
- **Final completion:** 2020-12-17
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2021-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643249, "Drug-drug Interaction Study of KL1333 in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04643249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*